Phase III SOLE: Continuous vs Intermittent Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer

June 2-6, 2017; Chicago, Illinois
Extended intermittent letrozole did not improve DFS or other efficacy outcomes compared with continuous dosing.
Format: Microsoft PowerPoint (.ppt)
File Size: 277 KB
Released: June 8, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

DESTINY-Breast03 trial: trastuzumab deruxtecan showed clinically meaningful PFS benefit compared with trastuzumab emtansine in previously treated HER2+ metastatic breast cancer; ESMO 2021 coverage from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 23, 2021

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Interactive online tool with strategies to assess and manage AEs associated with oral targeted therapy for HR+, HER2– breast cancer, from Clinical Care Options

Donna M. Fitzgerald, PA-C, MPAS Matthew P. Goetz, MD Marissa Marti, APRN, AGNP-C, AOCNP Joyce O'Shaughnessy, MD Laura M. Spring, MD Released: September 14, 2021

Downloadable slideset with the latest expert insights on CDK4/6 inhibitors for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: August 24, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue